Gujarat Kidney and Super Speciality Hospital Ltd. to Issue 2.2 Crore Equity Shares Through IPO. Funds Raised Will Be Utilized for Acquisitions, New Equipment, and Loan Repayment.
IPO Details: Gujarat Kidney and Super Speciality Hospital Limited (GKASSL) has recently filed its Draft Red Herring Prospectus (DRHP) with SEBI. The company plans to issue 2.2 crore equity shares with a face value of ₹10 per share. The price band for the issue will be announced shortly.
Issue Allotment and Fund Utilization
This public offering will have approximately 75% reserved for Qualified Institutional Buyers (QIBs), 10% for retail investors, and 15% for Non-Institutional Investors (NIIs). The funds raised through this IPO will be used for the acquisition of Parekh Hospital in Ahmedabad, payment for the previously acquired Ashwini Medical Centre, establishment of a new hospital in Vadodara, purchase of robotics equipment for the Vadodara hospital, repayment of company loans, and general corporate purposes.
Company Introduction
Established in 2019, Gujarat Kidney and Super Speciality Limited (GKASSL) is a leading healthcare company providing multi-specialty healthcare services across various cities in Gujarat. The company specializes in secondary and tertiary care services and offers high-quality medical facilities.
Operations and Financial Performance
As of March 20, 2025, Gujarat Kidney and Super Speciality Limited operates six multi-specialty hospitals and three pharmacies in major cities across Gujarat. These hospitals have a total bed capacity of 400, of which 355 beds are approved and 250 are operational.
In fiscal year 2024, the company's revenue was ₹18.72 crore, and its profit after tax was ₹5.63 crore. In the current fiscal year, as of September 30, 2024, the company's revenue was ₹5.48 crore, and its profit after tax was ₹1.71 crore.
IPO and Management
Nirvay Capital Services Private Limited is the book-running lead manager for this IPO, while Link Intime India Private Limited is the registrar for the issue.
